guest ::
| Home > Publications database > Ligand binding to anti-cancer target CD44 investigated by molecular simulations > print |
| Home > Publications database > Ligand binding to anti-cancer target CD44 investigated by molecular simulations > print |
| 001 | 820505 | ||
| 005 | 20240625095121.0 | ||
| 024 | 7 | _ | |a 10.1007/s00894-016-3029-6 |2 doi |
| 024 | 7 | _ | |a 0948-5023 |2 ISSN |
| 024 | 7 | _ | |a 1610-2940 |2 ISSN |
| 024 | 7 | _ | |a WOS:000379014700020 |2 WOS |
| 024 | 7 | _ | |a altmetric:9095968 |2 altmetric |
| 024 | 7 | _ | |a pmid:27342250 |2 pmid |
| 037 | _ | _ | |a FZJ-2016-05799 |
| 082 | _ | _ | |a 540 |
| 100 | 1 | _ | |a Nguyen, Tin Trung |b 0 |
| 245 | _ | _ | |a Ligand binding to anti-cancer target CD44 investigated by molecular simulations |
| 260 | _ | _ | |a Berlin |c 2016 |b Springer |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1478268519_17704 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a CD44 is a cell-surface glycoprotein and receptor for hyaluronan, one of the major components of the tumor extracellular matrix. There is evidence that the interaction between CD44 and hyaluronan promotes breast cancer metastasis. Recently, the molecule F-19848A was shown to inhibit hyaluronan binding to receptor CD44 in a cell-based assay. In this study, we investigated the mechanism and energetics of F-19848A binding to CD44 using molecular simulation. Using the molecular mechanics/Poisson Boltzmann surface area (MM-PBSA) method, we obtained the binding free energy and inhibition constant of the complex. The van der Waals (vdW) interaction and the extended portion of F-19848A play key roles in the binding affinity. We screened natural products from a traditional Chinese medicine database to search for CD44 inhibitors. From combining pharmaceutical requirements with docking and molecular dynamics simulations, we found ten compounds that are potentially better or equal to the F-19848A ligand at binding to CD44 receptor. Therefore, we have identified new candidates of CD44 inhibitors, based on molecular simulation, which may be effective small molecules for the therapy of breast cancer. |
| 536 | _ | _ | |a 899 - ohne Topic (POF3-899) |0 G:(DE-HGF)POF3-899 |c POF3-899 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef |
| 700 | 1 | _ | |a Tran, Duy Phuoc |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Huy, Pham Dinh Quoc |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Hoang, Zung |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Carloni, Paolo |0 P:(DE-Juel1)145614 |b 4 |e Corresponding author |
| 700 | 1 | _ | |a Van Pham, Phuc |0 P:(DE-HGF)0 |b 5 |e Corresponding author |
| 700 | 1 | _ | |a Nguyen, Chuong |0 P:(DE-HGF)0 |b 6 |e Corresponding author |
| 700 | 1 | _ | |a Li, Mai Suan |0 P:(DE-HGF)0 |b 7 |e Corresponding author |
| 773 | _ | _ | |a 10.1007/s00894-016-3029-6 |g Vol. 22, no. 7, p. 165 |0 PERI:(DE-600)1284729-x |n 7 |p 165 |t Journal of molecular modeling |v 22 |y 2016 |x 0948-5023 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/820505/files/art_10.1007_s00894-016-3029-6.pdf |y Restricted |
| 856 | 4 | _ | |x icon |u https://juser.fz-juelich.de/record/820505/files/art_10.1007_s00894-016-3029-6.gif?subformat=icon |y Restricted |
| 856 | 4 | _ | |x icon-1440 |u https://juser.fz-juelich.de/record/820505/files/art_10.1007_s00894-016-3029-6.jpg?subformat=icon-1440 |y Restricted |
| 856 | 4 | _ | |x icon-180 |u https://juser.fz-juelich.de/record/820505/files/art_10.1007_s00894-016-3029-6.jpg?subformat=icon-180 |y Restricted |
| 856 | 4 | _ | |x icon-640 |u https://juser.fz-juelich.de/record/820505/files/art_10.1007_s00894-016-3029-6.jpg?subformat=icon-640 |y Restricted |
| 856 | 4 | _ | |x pdfa |u https://juser.fz-juelich.de/record/820505/files/art_10.1007_s00894-016-3029-6.pdf?subformat=pdfa |y Restricted |
| 909 | C | O | |o oai:juser.fz-juelich.de:820505 |p VDB |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 4 |6 P:(DE-Juel1)145614 |
| 913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF3-890 |0 G:(DE-HGF)POF3-899 |2 G:(DE-HGF)POF3-800 |v ohne Topic |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |
| 914 | 1 | _ | |y 2016 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a No Authors Fulltext |0 StatID:(DE-HGF)0550 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1150 |2 StatID |b Current Contents - Physical, Chemical and Earth Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J MOL MODEL : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)IAS-5-20120330 |k IAS-5 |l Computational Biomedicine |x 0 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-9-20140121 |k INM-9 |l Computational Biomedicine |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)IAS-5-20120330 |
| 980 | _ | _ | |a I:(DE-Juel1)INM-9-20140121 |
| 981 | _ | _ | |a I:(DE-Juel1)INM-9-20140121 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|